Venture Capital, Private Equity, Public Equity · Palo Alto (United States), Singapore (Singapore), Hong Kong (Hong Kong), Beijing (China), Shanghai (China), Taipei (Taiwan) · Founded 1996
Vivo Capital is a global healthcare investment platform with a diverse, multi-fund investment platform spanning venture capital, growth equity, buyout, and public equities.
Series A, Series B, Series C
BioTech, MedTech, SaaS
Aadi Bioscience, Ablaze Pharmaceuticals, ADARx Pharmaceuticals, Adaxion Therapeutics, Aerobiotix, Agno Pharma, AkiraBio, Aligos Therapeutics, Ascendis Pharma, Aslan Pharmaceuticals, Avadel Pharmaceuticals, Avistone Pharmaceuticals, BlossomHill Therapeutics, Bolt Biotherapeutics, Bonraybio, Bonum Therapeutics, Caidya, Cidara Therapeutics, Clasp Therapeutics, Codexis, Compass Pathways, Compass Therapeutics, Createrna Science and Technology, Epibiologics, Esco Lifesciences Group, Evaheart, Fortis Therapeutics, Genetron, HanchorBio, HCMed Innovations, Histowiz, Homology Medicines, Immune-Onc Therapeutics, ImmunEdge, Innocare, Inspirna, Instil Bio, IO Biotech, IVERIC Bio, Kira Pharmaceuticals, Larimar Therapeutics, Lepu Biopharm, Lepu Scientech, Maculogix, Mereo BioPharma Group, Metacrine, Neocis, Neurogastrx, New Frontier Corporation, Ossium Health, Outrigger Therapeutics, Precision BioSciences, Provivi, Pulmocide, RareStone Group, Rayzebio, Regulus Therapeutics, RemeGen, Rgenta Therapeutics, RiboX Therapeutics, Ronovo Surgical, Satsuma Pharmaceuticals, Scientia Vascular, Sera Prognostics, Seran Bioscience, Sierra Oncology, Silence Therapeutics, Sinovac Biotech, Sinovac Life & Sciences, Suzhou Omini Pharmaeutical, Tarsus Pharmaceuticals, Tebra Technologies, Tenax Therapeutics, Terns Pharmaceuticals, TOT Biopharm, Tourmaline Bio, Tranquis Therapeutics, Vellum Biotechnology, Verastem, Verona Pharma, Visen Pharmaceuticals, Visirna Therapeutics, Wanmei Interactive, WuXi PharmaTech, Zai Lab, Zenas Biopharma